Other Information.
−Removed: None of the Company's directors and officers adopted, modified, or terminated a Rule 10b-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company's fiscal quarter ended June 30, 2025 (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended).
+Added: None of the Company's directors and officers adopted, modified, or terminated a Rule 10b-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company's fiscal quarter ended December 31, 2025 (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended).
EXHIBIT INDEX
−Removed: Employment Agreement, dated April 3, 2025, by and between the Company and Peter Weiler (included as Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on April 4, 2025, and incorporated herein by reference).
−Removed: Consulting Agreement, dated May 12, 2025, by and between Edesa Biotech Research, Inc.
−Removed: and Stephen Lemieux (included as Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q, filed on May 14, 2025, and incorporated herein by reference)
−Removed: Amendment No.
−Removed: 4 to Edesa Biotech, Inc.
−Removed: 2019 Equity Incentive Compensation Plan (included as Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on May 28, 2025, and incorporated herein by reference).
+Added: Amendment Agreement No.
+Added: 1 to Strategic Innovation Fund Agreement, dated September 30, 2025, by and among Edesa Biotech Research, Inc., Edesa Biotech, Inc., and his Majesty the King in right of Canada as represented by the Minister of Industry (included as Exhibit 10.42 to the Company’s Annual Report on Form 10-K filed on December 12, 2025 and incorporated herein by reference).
Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
13 unchanged sentences
under the Securities Act of 1933, as amended, or the Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
−Removed: Management contract or compensatory plan or arrangement.
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
−Removed: August 8, 2025
+Added: February 13, 2026
EDESA BIOTECH, INC.
2 unchanged sentences
(Principal Executive Officer)
−Removed: August 8, 2025
−Removed: /s/ Peter Weiler
−Removed: Peter Weiler, Chief Financial Officer
+Added: February 13, 2026
+Added: Weiler, Chief Financial Officer
(Principal Financial Officer and Duly Authorized Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.